The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
ORLANDO, FL / ACCESSWIRE / June 20, 2024 / Nutriband Inc.("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) provides an update on its Aversa Fentanyl product development program to shareholders as it aims to com...
ORLANDO, FL / ACCESSWIRE / June 3, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today reported Q1 revenues of $408,532 emphasizing its focus on expanding the company's Kinesiology Tape manufactu...
The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placement ORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a develo...
ORLANDO, FL / ACCESSWIRE / April 23, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that following its engagement by Fit For Life Group (FFL), a major brand license holder, on Apri...
Nutriband is targeting a 505(b)(2) NDA to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025 ORLANDO, FL / ACCESSWIRE / April 19, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a comp...
Data highlights the incidence of abuse and accidental pediatric exposure of transdermal patches containing opioid and stimulant drugs Nutriband's AVERSA™ technology addresses the unmet need for safe...
ORLANDO, FL / ACCESSWIRE / March 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that da...
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st. ORLANDO, FL / ACCESSWIRE / January 29, 2024 / Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today ann...
ORLANDO, FL / ACCESSWIRE / January 26, 2024 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights ...